A Phase 1 Food Effect Study of TAK-536TCH Final Formulation Tablet

NCT02348658 | Completed Phase 1 Results

• 3 other identifiers: TAK-536TCH/CPH-004U1111-1165-5595JapicCTI-152777
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

This is a phase 1, randomized, open-label, crossover study to evaluate the food-effect of single oral dose of TAK-536TCH final formulation tablet in healthy adult male participants.

Conditions

Hypertension

Keywords

Pharmacological therapy

Outcome Measures

Primary Outcomes (10)

• Cmax: Maximum Plasma Concentration for TAK-536, Its Metabolites (M-I and M-II) and Hydrochlorothiazide (HCTZ)

  Day 1: predose and at multiple time points (up to 48 hours) postdose in each period

• Cmax: Maximum Plasma Concentration for Amlodipine Besilate (AML)

  Day 1: predose and at multiple time points (up to 120 hours) postdose in each period

• AUC(0-48): Area Under the Plasma Concentration-Time Curve From Time 0 to 48 Hours Postdose in Each Period for TAK-536, Its Metabolites (M-I and M-II) and HCTZ

  AUC(0-48) is a measure of the area under the plasma concentration time-curve from time 0 to 48 hours postdose.

  Day 1: predose and at multiple time points (up to 48 hours) postdose in each period

• AUC(0-120): Area Under the Plasma Concentration-Time Curve From Time 0 to 120 Hours Postdose in Each Period for AML

  AUC(0-120) is a measure of the area under the plasma concentration time-curve from time 0 to 120 hours postdose.

  Day 1: predose and at multiple time points (up to 120 hours) postdose in each period

• AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration in Each Period for TAK-536, Its Metabolites (M-I and M-II) and HCTZ

  AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC\[0-tlqc\]).

  Day 1: predose and at multiple time points (up to 48 hours) postdose in each period

• AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration in Each Period for AML

  AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC\[0-tlqc\]).

  Day 1: predose and at multiple time points (up to 120 hours) postdose in each period

• AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity in Each Period for TAK-536, Its Metabolites (M-I and M-II) and HCTZ

  AUC (0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.

  Day 1: predose and at multiple time points (up to 48 hours) postdose in each period

• AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for AML

  AUC (0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.

  Day 1: predose and at multiple time points (up to 120 hours) postdose in each period

• Urinary Excretion Ratio of TAK-536, Its Metabolites (M-I and M-II) and HCTZ

  Urinary excretion ratio (percent \[%\] of dose) of TAK-536, its metabolite M-I, M-II and HCTZ in urine were calculated for each participant. Ratio was calculated from the urine concentrations of each analyte and the volume of urine collected in each pooling period.

  Day 1: predose and at multiple time-points (up to 48 hours) postdose in each period

• Urinary Excretion Ratio of AML

  Urinary excretion ratio (% of dose) of AML in urine were calculated for each participant. Ratio was calculated from the urine concentrations of each analyte and the volume of urine collected in each pooling period.

  Day 1: predose and at multiple time-points (up to 120 hours) postdose in each period

Secondary Outcomes (5)

• Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)

  Baseline up to 14 days after last dose of study drug (14 days after Day 1 of Period 2 )

• Number of Participants With TEAEs Related to Vital Signs

  Baseline up to 14 days after last dose of study drug (14 days after Day 1 of Period 2 )

• Number of Participants With TEAEs Related to Body Weight

  Baseline up to 14 days after last dose of study drug (14 days after Day 1 of Period 2 )

• Number of Participants With TEAEs Categorized Into Investigations System Organ Class (SOC) Related to Laboratory Values

  Baseline up to 14 days after last dose of study drug (14 days after Day 1 of Period 2 )

• Number of Participants With Clinical Significant Findings in Electrocardiograms After Study Drug Administration

  Baseline up to 14 days after last dose of study drug (14 days after Day 1 of Period 2 )

Study Arms (2)

Fasted dosing followed by fed dosing

OTHER

Dosing in the fasted state followed by fed dosing

Drug: TAK-536TCH

Fed dosing followed by fasted dosing

OTHER

Dosing in the fed state followed by fasted dosing

Drug: TAK-536TCH

Interventions

TAK-536TCH DRUG

TAK-536TCH tablets

Fasted dosing followed by fed dosing; Fed dosing followed by fasted dosing

Eligibility Criteria

• Age: 20 Years - 35 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• \. In the opinion of the investigator and subinvestigator, the participant is capable of understanding and complying with protocol requirements.
• \. The participant signs and dates a written, informed consent form prior to the initiation of any study procedures.
• \. The participant is a healthy Japanese adult male. 4. The participant is aged 20 to 35 years, inclusive at the time of informed consent.
• \. The participant weighs at least 50.0 kg and has a body mass index (BMI) from 18.5 to 25.0 kilograms per square meter (kg/m\^2), inclusive at Screening.

You may not qualify if:

• Participant has systolic blood pressure less-than (\<) 90 millimeters of mercury (mmHg) at Screening.
• Participant has suspected hypotension and associated physical findings, such as dizziness postural, facial pallor, or cold sweats based on evaluation/physical examination at Screening, on Day -1 of Period 1, or up to administration on the Period 1.
• The participant has received any study drug within 16 weeks (that is \[i.e.\], 112 days) prior to study drug administration of Period 1.
• The participant has received TAK-491\*, TAK-536, amlodipine, or hydrochlorothiazide in a previous clinical study or as a therapeutic agent.
• The participant has uncontrolled, clinically significant neurologic, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urological, or endocrine disease, or other abnormality (other than the disease studied), which could impact the ability of the participant to participate or potentially confound the study results.
• Participant has a known hypersensitivity to drugs.
• Participant has a positive urine drug result for drugs of abuse at Screening.
• Participant has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 2 years prior to the Screening visit or was unwilling to agree to abstain from alcohol and drugs throughout the study.
• Participant required any prohibited concomitant drugs, vitamins, or food products listed in the prohibited concomitant drugs and foods table.
• Participant has current or recent (within 6 months) gastrointestinal disease that would be expected to influence the absorption of drugs (i.e., a history of malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis, frequent \[more than once per week\] occurrence of heartburn, or any surgical intervention \[e.g., cholecystectomy\]).
• Participant has a history of cancer.
• Participant has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody/antigen, or serological reactions for syphilis at Screening.
• Participant has poor peripheral venous access.
• Participant has undergone whole blood collection of at least 200 mL within 4 weeks (28 days) or at least 400 mL within 12 weeks (84 days) prior to study drug administration in Period 1.
• Participant has undergone whole blood collection of at least 800 mL in total within 52 weeks (364 days) prior to study drug administration in Period 1.

Sponsors & Collaborators

• Takeda: lead

Study Sites (1)

Unknown Facility

Fukuoka, Fukuoka, Japan

Location

MeSH Terms

Conditions

Hypertension

Condition Hierarchy (Ancestors)

Vascular Diseases; Cardiovascular Diseases

Results Point of Contact

• Title: Medical Director
• Organization: Takeda

clinicaltrialregistry@tpna.com

+1-877-825-3327

Study Officials

• Study Manager

  Takeda

  STUDY CHAIR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 15, 2015
• First Posted: January 28, 2015
• Study Start: January 1, 2015
• Primary Completion: March 1, 2015
• Study Completion: March 1, 2015
• Last Updated: April 26, 2016
• Results First Posted: April 26, 2016

Record last verified: 2016-03

Locations

JP (1)